Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, Garrett Frampton, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Jaime Ferrer-Lozano, Jose A. Perez-Fidalgo, Massimo Cristofanilli, Henry Goḿez, Carlos L. Arteaga, Jennifer Giltnane, Justin M. Balko, Maureen T. Cronin, Mirna Jarosz, James Sun, Matthew Hawryluk, Doron Lipson, Geoff Otto, Jeffrey S. RossAddie Dvir, Lior Soussan-Gutman, Ido Wolf, Tamar Rubinek, Lauren Gilmore, Stuart Schnitt, Steven E. Come, Lajos Pusztai, Philip Stephens, Myles Brown, Vincent A. Miller

Research output: Contribution to journalArticle

266 Citations (Scopus)

Abstract

Purpose: We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations. Experimental Design: We studied a total of 249 tumor specimens from 208 patients. The specimens include 134 ER-positive (ER+/HER2-) and, as controls, 115 ER-negative (ER -) tumors. The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples. All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an additional 182 cancer-related genes. Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease. Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%-21%] in metastatic tumors and in a subgroup of patients who received an average of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%-41%). These mutations were not detected in primary or treatment-naïve ER+ cancer or in any stage of ER- disease. Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments. Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.

Original languageEnglish (US)
Pages (from-to)1757-1767
Number of pages11
JournalClinical Cancer Research
Volume20
Issue number7
DOIs
StatePublished - Apr 1 2014

Fingerprint

Estrogen Receptors
Breast Neoplasms
Mutation
Neoplasms
Confidence Intervals
Neoplasm Genes
Mutation Rate
Codon
Research Design
Therapeutics
Hormones
Ligands
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., ... Miller, V. A. (2014). Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical Cancer Research, 20(7), 1757-1767. https://doi.org/10.1158/1078-0432.CCR-13-2332

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. / Jeselsohn, Rinath; Yelensky, Roman; Buchwalter, Gilles; Frampton, Garrett; Meric-Bernstam, Funda; Gonzalez-Angulo, Ana Maria; Ferrer-Lozano, Jaime; Perez-Fidalgo, Jose A.; Cristofanilli, Massimo; Goḿez, Henry; Arteaga, Carlos L.; Giltnane, Jennifer; Balko, Justin M.; Cronin, Maureen T.; Jarosz, Mirna; Sun, James; Hawryluk, Matthew; Lipson, Doron; Otto, Geoff; Ross, Jeffrey S.; Dvir, Addie; Soussan-Gutman, Lior; Wolf, Ido; Rubinek, Tamar; Gilmore, Lauren; Schnitt, Stuart; Come, Steven E.; Pusztai, Lajos; Stephens, Philip; Brown, Myles; Miller, Vincent A.

In: Clinical Cancer Research, Vol. 20, No. 7, 01.04.2014, p. 1757-1767.

Research output: Contribution to journalArticle

Jeselsohn, R, Yelensky, R, Buchwalter, G, Frampton, G, Meric-Bernstam, F, Gonzalez-Angulo, AM, Ferrer-Lozano, J, Perez-Fidalgo, JA, Cristofanilli, M, Goḿez, H, Arteaga, CL, Giltnane, J, Balko, JM, Cronin, MT, Jarosz, M, Sun, J, Hawryluk, M, Lipson, D, Otto, G, Ross, JS, Dvir, A, Soussan-Gutman, L, Wolf, I, Rubinek, T, Gilmore, L, Schnitt, S, Come, SE, Pusztai, L, Stephens, P, Brown, M & Miller, VA 2014, 'Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer', Clinical Cancer Research, vol. 20, no. 7, pp. 1757-1767. https://doi.org/10.1158/1078-0432.CCR-13-2332
Jeselsohn, Rinath ; Yelensky, Roman ; Buchwalter, Gilles ; Frampton, Garrett ; Meric-Bernstam, Funda ; Gonzalez-Angulo, Ana Maria ; Ferrer-Lozano, Jaime ; Perez-Fidalgo, Jose A. ; Cristofanilli, Massimo ; Goḿez, Henry ; Arteaga, Carlos L. ; Giltnane, Jennifer ; Balko, Justin M. ; Cronin, Maureen T. ; Jarosz, Mirna ; Sun, James ; Hawryluk, Matthew ; Lipson, Doron ; Otto, Geoff ; Ross, Jeffrey S. ; Dvir, Addie ; Soussan-Gutman, Lior ; Wolf, Ido ; Rubinek, Tamar ; Gilmore, Lauren ; Schnitt, Stuart ; Come, Steven E. ; Pusztai, Lajos ; Stephens, Philip ; Brown, Myles ; Miller, Vincent A. / Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 7. pp. 1757-1767.
@article{183c5c86b2a34fcb9b082b5823deecae,
title = "Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer",
abstract = "Purpose: We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations. Experimental Design: We studied a total of 249 tumor specimens from 208 patients. The specimens include 134 ER-positive (ER+/HER2-) and, as controls, 115 ER-negative (ER -) tumors. The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples. All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an additional 182 cancer-related genes. Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease. Overall, the frequency of these mutations was 12{\%} [9/76; 95{\%} confidence interval (CI), 6{\%}-21{\%}] in metastatic tumors and in a subgroup of patients who received an average of 7 lines of treatment the frequency was 20{\%} (5/25; 95{\%} CI, 7{\%}-41{\%}). These mutations were not detected in primary or treatment-na{\"i}ve ER+ cancer or in any stage of ER- disease. Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments. Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.",
author = "Rinath Jeselsohn and Roman Yelensky and Gilles Buchwalter and Garrett Frampton and Funda Meric-Bernstam and Gonzalez-Angulo, {Ana Maria} and Jaime Ferrer-Lozano and Perez-Fidalgo, {Jose A.} and Massimo Cristofanilli and Henry Goḿez and Arteaga, {Carlos L.} and Jennifer Giltnane and Balko, {Justin M.} and Cronin, {Maureen T.} and Mirna Jarosz and James Sun and Matthew Hawryluk and Doron Lipson and Geoff Otto and Ross, {Jeffrey S.} and Addie Dvir and Lior Soussan-Gutman and Ido Wolf and Tamar Rubinek and Lauren Gilmore and Stuart Schnitt and Come, {Steven E.} and Lajos Pusztai and Philip Stephens and Myles Brown and Miller, {Vincent A.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-13-2332",
language = "English (US)",
volume = "20",
pages = "1757--1767",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

AU - Jeselsohn, Rinath

AU - Yelensky, Roman

AU - Buchwalter, Gilles

AU - Frampton, Garrett

AU - Meric-Bernstam, Funda

AU - Gonzalez-Angulo, Ana Maria

AU - Ferrer-Lozano, Jaime

AU - Perez-Fidalgo, Jose A.

AU - Cristofanilli, Massimo

AU - Goḿez, Henry

AU - Arteaga, Carlos L.

AU - Giltnane, Jennifer

AU - Balko, Justin M.

AU - Cronin, Maureen T.

AU - Jarosz, Mirna

AU - Sun, James

AU - Hawryluk, Matthew

AU - Lipson, Doron

AU - Otto, Geoff

AU - Ross, Jeffrey S.

AU - Dvir, Addie

AU - Soussan-Gutman, Lior

AU - Wolf, Ido

AU - Rubinek, Tamar

AU - Gilmore, Lauren

AU - Schnitt, Stuart

AU - Come, Steven E.

AU - Pusztai, Lajos

AU - Stephens, Philip

AU - Brown, Myles

AU - Miller, Vincent A.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Purpose: We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations. Experimental Design: We studied a total of 249 tumor specimens from 208 patients. The specimens include 134 ER-positive (ER+/HER2-) and, as controls, 115 ER-negative (ER -) tumors. The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples. All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an additional 182 cancer-related genes. Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease. Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%-21%] in metastatic tumors and in a subgroup of patients who received an average of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%-41%). These mutations were not detected in primary or treatment-naïve ER+ cancer or in any stage of ER- disease. Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments. Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.

AB - Purpose: We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations. Experimental Design: We studied a total of 249 tumor specimens from 208 patients. The specimens include 134 ER-positive (ER+/HER2-) and, as controls, 115 ER-negative (ER -) tumors. The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples. All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an additional 182 cancer-related genes. Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease. Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%-21%] in metastatic tumors and in a subgroup of patients who received an average of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%-41%). These mutations were not detected in primary or treatment-naïve ER+ cancer or in any stage of ER- disease. Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments. Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84898717745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898717745&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2332

DO - 10.1158/1078-0432.CCR-13-2332

M3 - Article

C2 - 24398047

AN - SCOPUS:84898717745

VL - 20

SP - 1757

EP - 1767

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -